November 2016 Vol 7, No 10
In recent years, the cancer patient’s experience has been recognized as an important factor in determining the value of a treatment. According to patient reports, their quality of life (QOL) remained stable on the immunotherapy nivolumab, whereas it significantly deteriorated on chemotherapy, as shown in an analysis of a phase 3 study of platinum-refractory, recurrent, metastatic head and neck cancer.
For many patients with advanced melanoma and lung cancer, checkpoint inhibitors have been a godsend, helping to extend survival to previously unthinkable lengths.
At the 2016 Palliative Care in Oncology Symposium, the message was clear and emphatic: We should care about caregivers as both co-deliverers and co-recipients of healthcare services.
Most oncologists’ knowledge about toxicities associated with newer therapies comes mainly from clinical trials, but publications of clinical trial safety results may be misleading, according to a study presented at the European Society for Medical Oncology 2016 Congress.
A simple quality improvement project to increase duration of hospice care for patients has doubled hospice length of stay, reaching the national median in 1 year.
- 1
- 2
Page 2 of 2
Results 11 - 15 of 15
Results 11 - 15 of 15
